Ken Griffin's position in Alnylam Pharmaceuticals is currently worth $25.9 Million. That's 0.03% of their equity portfolio (730th largest holding). The first Alnylam Pharmaceuticals trade was made in Q2 2013. Since then Ken Griffin bought shares 52 more times and sold shares on 57 occasions. The stake costed the investor $12.8 Million, netting the investor a gain of 103% so far.